BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer Clinical Trial

Official title:

A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined With Platinum-Based Chemotherapy ± Bevacizumab as First-Line Therapy For PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06123884
• Other study ID #: BAT-1308-002-CR
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: November 2023
• Est. completion date: August 2024

Study information

• Verified date: November 2023
• Source: Bio-Thera Solutions
• Contact: Juan Chen
• Phone: 18971436492
• Email: jchen[@]bio-thera.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer

Description:

The single-arm Phase II exploratory study designed to evaluate the safety and efficacy of the study drug will include 20-50 subjects to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab. Dynamic analysis will be conducted after the inclusion of 20 subject. If the safety of this combination regimen is manageable and the efficacy meets expectations, the enrollment in the Phase II study will be stopped and the Phase III study will be entered. The Phase III study is a randomized, double-blind, multicenter clinical study of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab versus placebo plus platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer. PFS and OS will be used as the combined endpoints, and a superiority design will be adopted with a total sample size of 476 subjects. Stratified block randomization will be performed based on the following random factors: patients will be stratified based on the presence of metastatic diseases at the time of diagnosis (Yes vs. No), PD-L1 CPS (1-10 vs. ≥ 10) and planned use of Bevacizumab (Yes vs. No).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 526
• Est. completion date: August 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

inclusion criteria:

1. Female patients, aged =18 years to =70 years, who voluntarily sign the informed consent form;

2. With persistent, recurrent or metastatic (the Federation International of Gynecology and Obstetrics [FIGO] Stage IVB) cervical cancer confirmed histologically (pathological reports required), including pathological types of squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma and clear-cell renal-cell carcinoma, not amenable to radical surgery and/or radical radiotherapy or radiochemotherapy, with no prior systemic anti-tumor therapy for persistent, recurrent or metastatic cervical cancer;

3. Subjects should be positive for PD-L1 expression (CPS = 1) in tumor specimens by the central laboratory. Subjects should provide sufficient formalin-fixed paraffin-embedded (FFPE) specimens or sections (6 sections recommended, not less than 3 sections), and be willing to undergo a tumor tissue biopsy for PD-L1 testing when necessary. The archival tissues must be representative tumor specimens collected within three years or unstained continuous sections of FFPE tumor tissues freshly resected within six months, and relevant pathological reports of the aforementioned specimens must also be provided. Both surgical resection and biopsy are acceptable methods for acquiring fresh tissue specimens; fine-needle aspiration and liquid-based cytology (TCT) samples (i.e., samples lacking complete tissue structures and providing only cell suspension and/or cell smears) are not acceptable; decalcified bone metastasis tumor tissue specimens are not acceptable;

4. At least one measurable tumor lesion per RECIST v1.1; lesions at sites previously treated with radiotherapy or other loco-regional therapies can only be considered as non-target lesions, unless unequivocal progression of the lesion occurs or the tumor activity of the lesion is confirmed by biopsy and the lesion is measurable

5. Life expectancy =12 weeks as evaluated by the investigator;

6. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1;

7. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and are willing to take effective birth control/contraceptive methods to prevent pregnancy during the study until 6 months after the last dose of the study drug. Postmenopausal women must have amenorrhea for at least 12 months before they are considered as women of non-childbearing potential.

9. Able to understand trial requirements, willing and able to comply with the trial and follow-up procedures.

exclusion criteria:

1. Subjects with other pathological types of cervical cancer, such as small cell carcinoma, sarcoma, etc.;

2. Pregnant or lactating women;

3. Prior radiotherapy within 14 days before the first dose. Except for palliative area radiotherapy for bone metastases for which pain cannot be effectively controlled by systemic therapy or local pain relief (radiotherapy area < 5% of bone marrow area); prior chemotherapeutic agents for increasing the sensitization to radiotherapy within 14 days before the first dose; prior use of traditional Chinese patent medicines or treatment with anti-tumor related functions as specified in the NMPA-approved package inserts within 14 days before the first dose, or Chinese herbal medicines for anti-tumor purposes clearly documented in the medical record ;

4. Patients who received live/attenuated vaccines and mRNA vaccines within 4 weeks prior to screening or scheduled to receive those vaccines during the study period;

5. Any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.) or therapies that target immune co-stimulatory molecules (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40, etc.);

6. AEs caused by prior anti-tumor therapy that are still > Grade 1 (as per CTCAE v5.0) before the first dose of the study drug (except for AEs, such as alopecia, fatigue, etc., that cannot be recovered to = Grade 1 and will remain stable for a long time as judged by the investigator based on actual clinical situations, except for Grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy); patients who previously experienced = Grade 3 irAEs or discontinued immunotherapy due to irAEs of any grade;

7. Active leptomeningeal disease or poorly controlled brain metastases. Patients with suspected or confirmed brain metastases are allowed to be enrolled if they have no obvious symptoms and the results of imaging examinations performed at least 28 days before the first dose of the study drug showed stable disease and no treatment (e.g., radiotherapy, surgery, or corticosteroid treatment) is required to control the symptoms of brain metastases within 28 days before the first dose of the study drug;

8. Patients who underwent major organ surgery (excluding aspiration biopsy) or experienced significant trauma within 4 weeks before the first dose of the study drug, or those who require elective surgery during the trial period;

9. Subjects with serious infections within 4 weeks before the first dose, including but not limited to the infection-related complications, bacteremia and severe pneumonia requiring hospitalization; subjects with active infection before the first dose are excluded;

10. Patients with the following infectious diseases: human immunodeficiency virus (HIV) infection; active hepatitis B virus infection [hepatitis B surface antigen (HBsAg) positive, and the result for hepatitis B virus deoxyribonucleic acid (HBV-DNA) test > 500 IU/ml or 103 copies/ml or above the upper limit of normal at the testing institution]; hepatitis C virus infection [anti-HCV antibodies and hepatitis C virus ribonucleic acid (HCV-RNA) test positive]; Treponema pallidum antibody positive and rapid plasma reagin (RPR) positive;

11. Subjects with tuberculosis untreated or under treatment, including but not limited to pulmonary tuberculosis; patients whose tuberculosis was cured after standardized anti-tuberculosis treatment as confirmed by the investigator may be included;

12. Subjects with known history of severe allergy or prior = Grade 3 allergic reactions to macromolecular protein preparations/monoclonal antibodies, and any component of the investigational drug;

13. Known to have any contraindication to cisplatin/carboplatin or paclitaxel, or allergy to any of their components;

14. Clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stent insertion as judged by the investigator;

15. Subjects with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;

16. Patients with active or potentially recurrent autoimmune disease (excluding patients with vitiligo, autoimmune thyroid disorder that can be treated with hormone replacement therapy, or type 1 diabetes mellitus);

17. Patients who required systemic treatment with glucocorticoid (>10 mg/day of prednisone or equivalent) or other immunosuppressive agents within 14 days before the first dose of the study drug, except for the following situations: ? topical, ocular, intra-articular, nasal, and inhaled glucocorticoid therapy; ? short-term use of glucocorticoid for prophylaxis (e.g., prevention of contrast allergy);

18. Subjects with a history of noninfectious pneumonitis requiring glucocorticoid therapy within 1 year before the first dose or with current interstitial lung disease;

19. History of severe cardiovascular and cerebrovascular disorders, including but not limited to: ? New York Heart Association (NYHA) Class II or above cardiac failure or left ventricular ejection fraction (LVEF) <50%; ? Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.; ? Acute coronary syndrome, congestive cardiac failure, aortic dissection, stroke, or other Grade 3 or above cardiovascular and cerebrovascular events within 6 months before the first dose; ? Clinically uncontrollable hypertension (defined in this protocol as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg despite the use of antihypertensive therapy);

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Recombinant humanized anti-PD-1 monoclonal antibody injection
Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
• Cisplatin
the usage and dosage should be determined by the investigator
• Bevacizumab Injection
Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
• carboplatin
the usage and dosage should be determined by the investigator
• Paclitaxel for Injection
the usage and dosage should be determined by the investigator

Locations

Country	Name	City	State
China	Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Bio-Thera Solutions

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase II study Primary endpoints:	Safety endpoints: Number of participants with abnormal vital signs	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Primary	Phase II study Primary endpoints:	Safety endpoints: Number of participants with abnormal physical examination	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Primary	Phase II study Primary endpoints:	Safety endpoints: Number of participants with various adverse events (AEs)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Primary	Phase II study Primary endpoints:	Safety endpoints: Number of participants with abnormal clinical laboratory tests	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Primary	Phase II study Primary endpoints:	Safety endpoints: Number of participants with abnormal clinical auxiliary tests	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Primary	Phase III study Primary endpoints:	Preliminary efficacy of the participants which is evaluated by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST V1.1)	Eevery 9 weeks during treatment from randomization up to Week 54, After week54 is every 12 weeks.
Secondary	Phase II study Secondary endpoints:	Preliminary efficacy of the participants which is evaluated by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST V1.1).	Eevery 9 weeks during treatment from randomization up to Week 54, After week54 is every 12 weeks
Secondary	Number of participants after single dose and multiple dose to Peak plasma concentration evaluation	Cmax	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple doses to PK characteristics evaluation	Tmax	AAt the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple dose to PK characteristics evaluation	T1/2	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple doses to PK characteristics	CL	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple dose to data point evaluation	AUC(0-t)	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple dose to area under the drug concentration-time curve evaluation	AUC(0-8)	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple doses to PK characteristics evaluation	Vd	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle1Day2,Cycle1Day3,Cycle1Day8,Cycle1Day15,Cycle2Day1,Cycle3Day1,Cycle3Day2,Cycle3Day3,Cycle3Day8,Cycle4Day1,Cycle5Day1,Cycle6Day1, after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple doses to immunogenicity evaluation.	Anti-drug antibodies (ADAs)	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle3Day1,Cycle5Day1,after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple dose to Immunogenicity evaluation when the ADA is positive.	neutralizing antibodies (NAbs)	At the Day of Cycle 1 (each Cycle is 21 Days),Cycle1Day1,Cycle3Day1,Cycle5Day1,after Cycle6, per 9 weeks.
Secondary	Phase III study Secondary endpoints:	Safety endpoints: Number of participants with abnormal vital signs	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Phase III study Secondary endpoints:	Safety endpoints: Number of participants with abnormal physical examination	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Phase III study Secondary endpoints:	Safety endpoints: Number of participants with abnormal various adverse events (AEs)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Phase III study Secondary endpoints:	Safety endpoints: Number of participants with abnormal clinical laboratory tests	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Phase III study Secondary endpoints:	Safety endpoints:Number of participants with abnormal clinical auxiliary tests	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Number of participants after single dose and multiple dose to immunogenicity evaluation.	Anti-drug antibodies (ADAs)	At the end of Cycle 1 (each cycle is 21 days),Cycel1Day1,cycle3Day1,Cycle5Day1,after Cycle6, per 9 weeks.
Secondary	Number of participants after single dose and multiple dose to Immunogenicity evaluation when the ADA is positive.	neutralizing antibodies (NAbs)	At the end of Cycle 1 (each cycle is 21 days),Cycel1Day1,cycle3Day1,Cycle5Day1,after Cycle6, per 9 weeks.